Learn More

A Novel Patented-Pending Combination Therapy for Cognitive Function, ADHD, and Narcolepsy

Modamane’s lead innovation is a UK patent-pending pharmaceutical composition that combines modafinil with Lion’s Mane (Hericium erinaceus) extract. This therapy is designed to enhance cognitive performance through a unique dual mechanism: dopaminergic wakefulness paired with neurotrophic support.

Patent pending (UK & USA), with international protection pathways and patent family expansion available and in progress.

The patent application covers pharmaceutical composition, methods of use, manufacturing processes, and combination therapy claims, providing a strong foundation for IP protection across multiple neurological and cognitive health applications.

Scientific Rationale

Modafinil

Modafinil is a well-established wakefulness-promoting agent used in narcolepsy, ADHD, shift-work sleep disorder, and cognitive performance enhancement.

It works primarily by inhibiting dopamine reuptake, improving alertness, focus, and executive functioning.


Lion’s Mane Extract (Hericium erinaceus)

Lion’s Mane contains neuroactive compounds (hericenones and erinacines) which stimulate nerve growth factor (NGF) synthesis.

NGF supports:

  • Neuronal growth

  • Synaptic plasticity

  • Neuroregeneration

  • Memory and cognitive resilience

These properties have been demonstrated in preclinical and early human studies.


Synergistic Mechanism

The patented-pending therapy leverages two complementary biological pathways:

  • Modafinil → Enhances wakefulness, alertness, and attentional capacity

  • Lion’s Mane → Promotes neurotrophic activity and neuronal maintenance

  • Combined → A differentiated strategy for cognitive improvement, expanding modafinil’s utility while supporting long-term neuronal health

This dual-action approach is not described in existing treatments and forms the basis of Modamane’s intellectual property.

Therapeutic Applications

The patent-pending formulation is being developed to several high-value clinical areas:

  • ADHD (enhanced attention and reduced hyperactivity)

  • Narcolepsy and excessive daytime sleepiness (improved wakefulness)

  • Cognitive impairment and mild memory decline

  • General cognitive enhancement

By combining symptomatic improvement with neurotrophic support, this therapy addresses both short-term performance and long-term cognitive health.


IP Position

The Modamane patent application provides a strong platform through:

  • Pharmaceutical composition claims: modafinil + Lion’s Mane extract

  • Defined ratio ranges ensuring synergistic effect

  • Manufacturing process claims, including extraction and formulation

  • Method-of-use claims for ADHD, narcolepsy, and cognitive enhancement

  • Combination therapy claims for simultaneous or sequential administration

Together, this establishes a robust, evolving IP position suitable for clinical development, partnership, and commercial licensing, with scope for further claim optimisation and additional filings.


Development & Partnership Opportunities

Modamane is seeking collaborations with:

  • Pharmaceutical manufacturers

  • Biotechnology companies

  • Digital therapeutics platforms

  • Clinical research organisations

    Opportunities include:

    • Full or partial licensing

    • Co-development agreements

    • Territory-exclusive partnerships

    • Clinical development alliances


    Our objective is to advance this patent-pending combination therapy through further validation and development, unlocking its therapeutic potential across multiple neurological and cognitive indications.




Contact Business Development